Lorglumide

Lorglumide

Clinical data
ATC code	none
Identifiers
IUPAC name N^2-(3,4-Dichlorobenzoyl-N,N-dipentyl-α-glutamine
Synonyms	4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
CAS Number	97964-56-2
PubChem (CID)	3960
IUPHAR/BPS	891
ChemSpider	3823
UNII	LAD1UQ73BE
ChEBI	CHEBI:88305
ChEMBL	CHEMBL24938
Chemical and physical data
Formula	C22H32Cl2N2O4
Molar mass	459.406 g/mol
3D model (Jmol)	Interactive image
SMILES CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
InChI InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28) Key:IEKOTSCYBBDIJC-UHFFFAOYSA-N
(what is this?)  (verify)

Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist,^[1] with fairly high selectivity for the CCK_A subtype.^[2] It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.^[3][4][5][6]

References

1. Makovec, F; Bani, M; Cereda, R; Chisté, R; Pacini, M. A.; Revel, L; Rovati, L. A.; Rovati, L. C.; Setnikar, I (1987). "Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists". Arzneimittel-Forschung. 37 (11): 1265–8. PMID 3440035.
2. González-Puga, C; García-Navarro, A; Escames, G; León, J; López-Cantarero, M; Ros, E; Acuña-Castroviejo, D (2005). "Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: Synergism with pharmacological levels of melatonin". Journal of Pineal Research. 39 (3): 243–50. doi:10.1111/j.1600-079X.2005.00239.x. PMID 16150104.
3. De Tullio, P; Delarge, J; Pirotte, B (1999). "Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists)". Current medicinal chemistry. 6 (6): 433–55. PMID 10213792.
4. De Tullio, P; Delarge, J; Pirotte, B (2000). "Therapeutic and chemical developments of cholecystokinin receptor ligands". Expert Opinion on Investigational Drugs. 9 (1): 129–46. doi:10.1517/13543784.9.1.129. PMID 11060666.
5. Herranz, R (2003). "Cholecystokinin antagonists: Pharmacological and therapeutic potential". Medicinal Research Reviews. 23 (5): 559–605. doi:10.1002/med.10042. PMID 12789687.
6. Berna, M. J.; Tapia, J. A.; Sancho, V; Jensen, R. T. (2007). "Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential". Current Opinion in Pharmacology. 7 (6): 583–92. doi:10.1016/j.coph.2007.09.011. PMC 2186776. PMID 17997137.